CA2723192A1 - Delivery of nucleic acid complexes from particles - Google Patents

Delivery of nucleic acid complexes from particles Download PDF

Info

Publication number
CA2723192A1
CA2723192A1 CA2723192A CA2723192A CA2723192A1 CA 2723192 A1 CA2723192 A1 CA 2723192A1 CA 2723192 A CA2723192 A CA 2723192A CA 2723192 A CA2723192 A CA 2723192A CA 2723192 A1 CA2723192 A1 CA 2723192A1
Authority
CA
Canada
Prior art keywords
nucleic acid
particles
acid complexes
complexes
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2723192A
Other languages
English (en)
French (fr)
Inventor
Joram Slager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surmodics Inc
Original Assignee
Surmodics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surmodics Inc filed Critical Surmodics Inc
Publication of CA2723192A1 publication Critical patent/CA2723192A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ceramic Engineering (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CA2723192A 2008-05-07 2009-05-07 Delivery of nucleic acid complexes from particles Abandoned CA2723192A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5104108P 2008-05-07 2008-05-07
US61/051,041 2008-05-07
PCT/US2009/043158 WO2009137689A2 (en) 2008-05-07 2009-05-07 Delivery of nucleic acid complexes from particles

Publications (1)

Publication Number Publication Date
CA2723192A1 true CA2723192A1 (en) 2009-11-12

Family

ID=40910992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2723192A Abandoned CA2723192A1 (en) 2008-05-07 2009-05-07 Delivery of nucleic acid complexes from particles

Country Status (5)

Country Link
US (1) US8936811B2 (enExample)
EP (1) EP2296630A2 (enExample)
JP (1) JP5763525B2 (enExample)
CA (1) CA2723192A1 (enExample)
WO (1) WO2009137689A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5763525B2 (ja) 2008-05-07 2015-08-12 サーモディクス，インコーポレイティド 粒子からの核酸複合体の送達
JP5592897B2 (ja) * 2008-12-26 2014-09-17 サムヤン バイオファーマシューティカルズ コーポレイション アニオン性薬物含有薬剤学的組成物及びその製造方法
WO2010118213A2 (en) * 2009-04-08 2010-10-14 Surmodics, Inc. Particles for delivery of nucleic acids and related devices and methods
WO2010118238A2 (en) 2009-04-08 2010-10-14 Surmodics, Inc. Controlled release devices and methods for delivery of nucleic acids
EP2386647A1 (de) * 2010-05-10 2011-11-16 Qiagen GmbH Verfahren zur Transfektion einer eurkaryotischen Zelle
US20110319473A1 (en) * 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
WO2012012541A2 (en) * 2010-07-21 2012-01-26 Allergan, Inc. SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
EP2636748A4 (en) * 2010-11-05 2014-04-02 Ezaki Glico Co SUGAR-CONTAINING AMINOGLUCAN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US9551680B2 (en) 2013-06-28 2017-01-24 Verily Life Sciences Llc Chemically reactive enzyme immobilization
US9828620B2 (en) 2013-06-28 2017-11-28 Verily Life Sciences Llc Porous polymeric formulation prepared using monomer
US9750445B2 (en) 2013-06-28 2017-09-05 Verily Life Sciences Llc Porous polymeric formulation prepared using porogens
US9441258B2 (en) * 2013-06-28 2016-09-13 Verily Life Sciences LLP Enzyme immobilization by crosslinking
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
EP3222273B1 (en) 2014-11-18 2019-09-25 National Institute for Materials Science Method for producing porous particle
AU2016372321B2 (en) * 2015-12-18 2019-01-24 Samyang Holdings Corporation Method for preparing polymeric micelle containing anionic drug
KR101882133B1 (ko) * 2017-02-21 2018-07-25 성균관대학교산학협력단 핵산과 결합 가능한 펩타이드를 이용하여 핵산을 분리하는 방법
WO2019126169A1 (en) * 2017-12-18 2019-06-27 C. R. Bard, Inc. Drug-loaded microbead compositions, embolization compositions and associated methods
US11590080B2 (en) 2017-12-18 2023-02-28 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents
US20240131184A1 (en) * 2019-10-10 2024-04-25 University Of Maryland, Baltimore Compositions and methods for delivering nucleic acids to cells
US20220313616A1 (en) * 2021-03-30 2022-10-06 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of Nucleic Acid-Encapsulated Particles
CN118879783B (zh) * 2024-07-04 2025-08-08 恒敬合创生物医药（浙江）有限公司 一种用于包裹核酸药物的环状脂肽载体

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2668156A (en) 1950-04-06 1954-02-02 Nat Starch Products Inc Unsaturated starch compounds and insoluble derivatives thereof
US4079025A (en) 1976-04-27 1978-03-14 A. E. Staley Manufacturing Company Copolymerized starch composition
US4060506A (en) 1976-04-27 1977-11-29 A. E. Staley Manufacturing Company Starch acrylamides and the method for preparing the same
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US5160745A (en) 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
EP0471036B2 (en) 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
EP0405917A1 (en) 1989-06-26 1991-01-02 Sequa Chemicals Inc. Starch polymer graft
US5116927A (en) 1989-06-27 1992-05-26 Sequa Chemicals, Inc. Starch polymer graft composition and method of preparation
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5736371A (en) 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
WO1993009176A2 (en) 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
CA2107683C (en) 1992-02-13 2004-07-20 Dale G. Swan Immobilization of chemical species in crosslinked matrices
DE4210334A1 (de) 1992-03-30 1993-10-07 Stoess & Co Gelatine Biologisch abbaubares, wasserresistentes Polymer-Material
US6277899B1 (en) 1992-08-03 2001-08-21 Novamont S.P.A. Biodegradable polymeric composition
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5414075A (en) 1992-11-06 1995-05-09 Bsi Corporation Restrained multifunctional reagent for surface modification
US5272181A (en) 1992-11-18 1993-12-21 Evergreen Solutions, Inc. Biodegradable expanded foam material
DE59306199D1 (de) 1992-11-30 1997-05-22 Ciba Geigy Ag Polymerisierbare kohlenhydratester, polymere daraus und deren verwendung
SE500964C2 (sv) 1993-01-19 1994-10-10 Medicarb Ab Fast bärare med modifierad yta varvid modifikationen åstadkommes genom en primer innehållande en polysackarid och förfarande för framställning av en sådan bärare
US5589577A (en) 1993-04-07 1996-12-31 Alko Group Ltd. Applications and methods for the preparation of fatty acid esters of polysaccharides
US5773021A (en) 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
EP0712635B1 (en) 1994-05-13 2003-05-02 Kuraray Co., Ltd. Medical polymer gel
AU2946295A (en) 1994-06-27 1996-01-19 Johns Hopkins University, The Targeted gene delivery system
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
TW362100B (en) 1995-07-21 1999-06-21 Novartis Ag The preparation and use of photochemically cross-linked polysaccharide derivatives having no photopolymerisable functional groups
JP2997995B2 (ja) 1995-09-13 2000-01-11 日本コーンスターチ株式会社 生分解性樹脂組成物の水系分散液
US5714360A (en) 1995-11-03 1998-02-03 Bsi Corporation Photoactivatable water soluble cross-linking agents containing an onium group
CA2173818A1 (fr) 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US20080131512A1 (en) 1996-07-01 2008-06-05 Wilhelmus Everhardus Hennink Biodegradable hydrogels
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
FR2753902B1 (fr) 1996-09-27 1999-04-02 Ioualalen Karim Nouveau type de matrice ionique biodegradable de polarite interne modulable a polymere greffe
US5879707A (en) 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
US5866165A (en) 1997-01-15 1999-02-02 Orquest, Inc. Collagen-polysaccharide matrix for bone and cartilage repair
JP3033508B2 (ja) 1997-01-20 2000-04-17 日本電気株式会社 生体内活動部位推定方法
CA2283461A1 (en) * 1997-03-14 1998-09-17 Uab Research Foundation Adenoviral vectors with modified tropism
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6121027A (en) 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
US6316522B1 (en) 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
DE19737481A1 (de) 1997-08-28 1999-03-04 Hoechst Ag Sphärische lineare Polysaccharide enthaltende Mikropartikel
US6284273B1 (en) 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6410044B1 (en) 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
US6007833A (en) 1998-03-19 1999-12-28 Surmodics, Inc. Crosslinkable macromers bearing initiator groups
FR2780901B1 (fr) 1998-07-09 2000-09-29 Coletica Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
CA2337890C (en) 1998-07-23 2009-01-27 Cooperatieve Verkoop-En Productievereniging Van Aardappelmeel En Derivaten Avebe B.A. An adhesive composition from derivatives of high amylopectin content root and tubular starches
AU5006999A (en) * 1998-07-23 2000-02-14 Johns Hopkins University School Of Medicine, The Controlled release of bioactive substances
US6514534B1 (en) 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
IT1303553B1 (it) 1998-09-01 2000-11-14 Novamont Spa Composizioni biodegradabili comprendenti amido ed esteri di cellulosa.
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
EP1156812A4 (en) 1999-02-23 2004-09-29 Isis Pharmaceuticals Inc MULTIPARTICULAR FORMULATION
DK1168934T3 (da) 1999-04-12 2008-05-13 Cornell Res Foundation Inc Hydrogeldannende system med hydrofobe og hydrofile komponenter
US6716445B2 (en) 1999-04-12 2004-04-06 Cornell Research Foundation, Inc. Hydrogel entrapping therapeutic agent and stent with coating comprising this
ATE248587T1 (de) * 1999-06-14 2003-09-15 Baxter Int Mikrosphären mit verzögerter wirkstoffabgabe
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
WO2002006507A1 (en) 2000-07-17 2002-01-24 Ezaki Glico Co., Ltd. Biodegradable articles obtained from enzymatically synthesized amylose
AU2001271417B2 (en) 2000-08-30 2006-10-05 Johns Hopkins University Devices for intraocular drug delivery
AU2001294890A1 (en) 2000-09-25 2002-04-02 Board Of Regents, The University Of Texas System Pei: dna vector formulations for in vitro and in vivo gene delivery
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
US6748954B2 (en) 2000-10-27 2004-06-15 The Regents Of The University Of Michigan Drug release from polymer matrices through mechanical stimulation
US6586493B1 (en) 2001-03-07 2003-07-01 Arizona Board Of Regents Arizona State University Polysaccharide-based hydrogels and pre-gel blends for the same
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
WO2003088925A2 (en) * 2002-04-18 2003-10-30 Carnegie Mellon University Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids
JP2005526972A (ja) 2002-05-02 2005-09-08 シファーゲン バイオシステムズ， インコーポレイテッド 多糖系ヒドロゲルをコーティングした表面を有するバイオチップ
US6715445B2 (en) * 2002-05-07 2004-04-06 Rolf C. Hagen, Inc. Bird cage
DE10223310A1 (de) 2002-05-24 2003-12-11 Biotronik Mess & Therapieg Verfahren zum Beschichten von Implantaten mit einer Polysaccharid-Lage
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004009664A2 (en) 2002-07-19 2004-01-29 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7862831B2 (en) 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US20050143363A1 (en) 2002-09-29 2005-06-30 Innorx, Inc. Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases
CA2509382A1 (en) 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
US20050025797A1 (en) 2003-04-08 2005-02-03 Xingwu Wang Medical device with low magnetic susceptibility
AU2004237774B2 (en) 2003-05-02 2009-09-10 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
KR101137785B1 (ko) * 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
US7514530B2 (en) 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
JP5026956B2 (ja) 2004-05-12 2012-09-19 サーモディクス，インコーポレイティド 医療用具のための天然生分解性多糖コーティング
DK1765294T3 (da) 2004-05-12 2008-11-10 Baxter Int Nukleinsyremikrokugler samt deres fremstilling og afgivelse
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
WO2006014484A2 (en) 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions
WO2006020818A2 (en) 2004-08-12 2006-02-23 The Sherwin-Williams Company Carbohydrate based alkyds
BRPI0518582A2 (pt) 2004-11-24 2008-11-25 Therakine Corp implante para liberaÇço de medicamento intra-ocular
US20060286071A1 (en) 2005-06-21 2006-12-21 Epstein Samuel J Therapeutic pastes for medical device coating
US8663673B2 (en) 2005-07-29 2014-03-04 Surmodics, Inc. Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility
JP5139301B2 (ja) 2005-09-21 2013-02-06 サーモディクス，インコーポレイティド 生分解性天然多糖を含む被膜及び器具
JP5139302B2 (ja) 2005-09-21 2013-02-06 サーモディクス，インコーポレイティド 天然生分解性多糖を用いたｉｎｓｉｔｕにおける閉塞物の形成方法
WO2007059144A1 (en) 2005-11-15 2007-05-24 Surmodics, Inc. Ultrasonic nozzles for applying two-component coatings
CA2636716C (en) 2006-01-13 2014-12-23 Surmodics, Inc. Microparticle containing matrices for drug delivery
CA2638915A1 (en) 2006-02-10 2007-08-23 The Regents Of The University Of California Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
CA2645324A1 (en) 2006-03-15 2007-09-27 Surmodics, Inc. Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof
US8968782B2 (en) 2006-06-28 2015-03-03 Surmodics, Inc. Combination degradable and non-degradable matrices for active agent delivery
WO2008002657A2 (en) 2006-06-28 2008-01-03 Surmodics, Inc. Microparticles containing active agent dispersed in a polymer matrix as implant or as coating for medical devices
EP2056883B1 (en) * 2006-08-04 2021-09-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20080089923A1 (en) 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
US20080154241A1 (en) 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
US8709827B2 (en) * 2007-06-28 2014-04-29 Surmodics, Inc. Polypeptide microparticles
WO2009064442A1 (en) 2007-11-13 2009-05-22 Brookwood Pharmaceuticals, Inc. Viscous terpolymers as drug delivery platform
WO2009091812A2 (en) 2008-01-14 2009-07-23 Surmodics, Inc. Devices and methods for elution of nucleic acid delivery complexes
JP5763525B2 (ja) 2008-05-07 2015-08-12 サーモディクス，インコーポレイティド 粒子からの核酸複合体の送達
US20110159098A1 (en) 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery

Also Published As

Publication number Publication date
WO2009137689A3 (en) 2010-01-21
JP5763525B2 (ja) 2015-08-12
EP2296630A2 (en) 2011-03-23
US20090280181A1 (en) 2009-11-12
JP2011520813A (ja) 2011-07-21
WO2009137689A2 (en) 2009-11-12
US8936811B2 (en) 2015-01-20

Similar Documents

Publication Publication Date Title
US8936811B2 (en) Device coated with glycogen particles comprising nucleic acid complexes
US20090186059A1 (en) Devices and methods for elution of nucleic acid delivery complexes
US8496954B2 (en) Coating systems for the controlled delivery of hydrophilic bioactive agents
US8142836B2 (en) Multi-layered coatings and methods for controlling elution of active agents
US7638344B2 (en) Active agent eluting matrices with particulates
JP5819579B2 (ja) 薬物送達のためのマトリックスを含む微粒子
US20110319473A1 (en) Compositions and methods for enhancement of nucleic acid delivery
US20120100187A1 (en) Coatings and methods for controlled elution of hydrophilic active agents
US8883208B2 (en) Particles for delivery of nucleic acids and related devices and methods
JP2015154943A (ja) 血液適合性表面を創出するためのポリマー
JP2007530169A (ja) 生物適合性表面を調製するための組成物及び方法
US20090263449A1 (en) Delivery of nucleic acid complexes from materials including negatively charged groups
US20110159098A1 (en) Stabilization and delivery of nucleic acid complexes
US20100008966A1 (en) Medical Devices and Methods for Delivery of Nucleic Acids
JP2008535563A (ja) 生物活性剤のためのコーティング組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140411

FZDE Discontinued

Effective date: 20190118